Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Fig. 5

IHMT-337 inhibits cell proliferation in different preclinical models in vitro and in vivo. a Body weight change in mice for each twice-daily dosing group of IHMT-337 and EPZ6438. Initial body weight was set as 100%. Comparison of the final tumor weight in each group of 22-day treatment period. b Relative tumor size measurements of Pfeiffer xenograft mice after IHMT-337 and EPZ6438 treatment. c Effects of 22 days IHMT-337 treatment on growth of Pfeiffer xenograft tumor model were determined. EPZ6438 was set as control. d Effects of 72 h IHMT-337 treatment on TNBC PDO models. e The inhibitory effects of IHMT-337 on protein levels of EZH2 and CDK4 in TNBC PDOs were determined by confocal assays. f The inhibitory effects of IHMT-337 on proliferation of TNBC PDOs were determined. EPZ6438 was set as control. g Transcriptional level of CDK4 in TNBC PDOs with or without IHMT-337 treatment were determined by Q-PCR. h IHMT-337 affects cell cycle progression through targeting transcriptional regulating of CDK4

Back to article page